Vasoactive and antiarrhythmic drugs during percutaneous coronary intervention

Bimmer E. Claessen; José P.S. Henriques

doi:https://doi.org/10.1016/j.iccl.2013.06.002

Vasoactive and antiarrhythmic drugs during percutaneous coronary intervention

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

The objective in percutaneous coronary intervention (PCI) is to treat flow-limiting atherothrombotic coronary plaques mechanically. Many types of antithrombotic drugs are used to prevent ischemic complications during manipulation of catheters, guidewires, balloons, and stents in coronary arteries while minimizing the risk of bleeding. However, many other types of pharmacologic agents are also used to facilitate PCI. This review focuses on the most commonly used adjunct drugs during PCI. In addition, a recommendation of which drugs should be stopped or interrupted in patients undergoing PCI is provided.

Original language	English
Pages (from-to)	665-670
Number of pages	6
Journal	Interventional Cardiology Clinics
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.iccl.2013.06.002
Publication status	Published - Oct 2013

Keywords

Adjunct pharmacology
Antiarrhythmics
Drug discontinuation
Percutaneous coronary intervention
Periprocedural myocardial infarction
Vasodilators

Access to Document

https://doi.org/10.1016/j.iccl.2013.06.002

Cite this

@article{c672c92663e74940af63edfb80911c77,

title = "Vasoactive and antiarrhythmic drugs during percutaneous coronary intervention",

abstract = "The objective in percutaneous coronary intervention (PCI) is to treat flow-limiting atherothrombotic coronary plaques mechanically. Many types of antithrombotic drugs are used to prevent ischemic complications during manipulation of catheters, guidewires, balloons, and stents in coronary arteries while minimizing the risk of bleeding. However, many other types of pharmacologic agents are also used to facilitate PCI. This review focuses on the most commonly used adjunct drugs during PCI. In addition, a recommendation of which drugs should be stopped or interrupted in patients undergoing PCI is provided.",

keywords = "Adjunct pharmacology, Antiarrhythmics, Drug discontinuation, Percutaneous coronary intervention, Periprocedural myocardial infarction, Vasodilators",

author = "Claessen, {Bimmer E.} and Henriques, {Jos{\'e} P.S.}",

year = "2013",

month = oct,

doi = "https://doi.org/10.1016/j.iccl.2013.06.002",

language = "English",

volume = "2",

pages = "665--670",

journal = "Interventional Cardiology Clinics",

issn = "2211-7458",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Vasoactive and antiarrhythmic drugs during percutaneous coronary intervention

AU - Claessen, Bimmer E.

AU - Henriques, José P.S.

PY - 2013/10

Y1 - 2013/10

N2 - The objective in percutaneous coronary intervention (PCI) is to treat flow-limiting atherothrombotic coronary plaques mechanically. Many types of antithrombotic drugs are used to prevent ischemic complications during manipulation of catheters, guidewires, balloons, and stents in coronary arteries while minimizing the risk of bleeding. However, many other types of pharmacologic agents are also used to facilitate PCI. This review focuses on the most commonly used adjunct drugs during PCI. In addition, a recommendation of which drugs should be stopped or interrupted in patients undergoing PCI is provided.

AB - The objective in percutaneous coronary intervention (PCI) is to treat flow-limiting atherothrombotic coronary plaques mechanically. Many types of antithrombotic drugs are used to prevent ischemic complications during manipulation of catheters, guidewires, balloons, and stents in coronary arteries while minimizing the risk of bleeding. However, many other types of pharmacologic agents are also used to facilitate PCI. This review focuses on the most commonly used adjunct drugs during PCI. In addition, a recommendation of which drugs should be stopped or interrupted in patients undergoing PCI is provided.

KW - Adjunct pharmacology

KW - Antiarrhythmics

KW - Drug discontinuation

KW - Percutaneous coronary intervention

KW - Periprocedural myocardial infarction

KW - Vasodilators

UR - http://www.scopus.com/inward/record.url?scp=84884987396&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.iccl.2013.06.002

DO - https://doi.org/10.1016/j.iccl.2013.06.002

M3 - Review article

SN - 2211-7458

VL - 2

SP - 665

EP - 670

JO - Interventional Cardiology Clinics

JF - Interventional Cardiology Clinics

IS - 4

ER -

Vasoactive and antiarrhythmic drugs during percutaneous coronary intervention

Abstract

Keywords

Access to Document

Other files and links

Cite this